Abstract
Cell replacement therapy offers a potential novel approach to repair the injured heart. For this, different cell types are considered to be transplanted to replace damaged tissue. To be able to regenerate the heart, cells should have the capability of differentiating into all cell types required for cardiac repair: functional cardiomyocytes, endothelial cells and smooth muscle cells. In the last decade, it was discovered that the heart was not a terminally differentiated organ. Additionally, progenitor cells could be isolated from the myocardium. It was suggested that these progenitors are an ideal candidate to regenerate the heart due to their localization. Many different types of cardiac progenitor cells (CPCs) or cardiac stem cells (CSCs) have been isolated from the heart
. CPCs are lineage negative and negative for haematopoietic markers as CD34 and CD45.
Previously, we reported the isolation of cardiomyocyte progenitor cells (CMPCs) from the human heart that are able to proliferate and efficiently differentiate into functional cardiomyocytes without requiring co-culture with neonatal myocytes [6, 7] . Three months after transplantation of CMPCs in a mouse model of myocardial infarction, we observed less outward remodelling and improved cardiac function as compared to control injections [8] . [9] [10] [11] . Therefore [12] [13] [14] . miR-155 is demonstrated to be involved in cell death in several cell lines [15] [16] [17] [19, 20] 
Although high numbers of cells were injected in several studies, few implanted cells survived, limiting their potential contribution for myocardial repair. Most of the engrafted cells died in the first 48 hrs after transplantation, partially due to the hostile microenvironment of the ischemic myocardium

Methods
CMPC isolation and culture
CMPCs were isolated and propagated as previously described [6] . Briefly, human foetal heart tissue was collected after elective abortion and individual permission using standard informed consent procedures and prior approval of the ethics committee of the University Medical Center Utrecht were obtained. The heart was cut into small pieces and digested by collagenase, followed by passing through a cell strainer to get a single cell suspension. CMPCs were further isolated via magnetic cell sorting using an iron-labelled mouse anti-Sca-1 antibody and characterized as described [6, 7, 21] . CMPCs differentiation experiment was performed as previously reported [6] . For our experiments we used six individual isolated CMPC cell-lines. 
Quantitative RT-PCR for miRNAs expression
Luciferase experiments
In a 12-well plate, HEK 293 cells were transfected with 400 ng luciferasereporter plasmid, containing the 3Ј-untranslated region (UTR) of Bach1 which is a validated target of miR-155 [23] (a generous gift from Dr. Erik Flemington), with 30 nM of miR-155, a combination of miR-155 and antimiR-155, or scr-miR. A total of 400 ng cytomegalovirus (CMV)-␤-galactosidase plasmid was co-transfected as an internal transfection efficiency control. After 48 hrs of transfection, cells were lysed and luciferase and ␤-galactosidase activities were measured with the Luciferase Assay System
and ␤-galactosidase Enzyme Assay System (Promega, Madison, WI, USA), respectively, as described [18] . 
Cell viability assay
Results
Increased expression of miR-155 in CMPCs
Because miR-155 overexpression did not alter cell proliferation [18] , we investigated if it could have a function in cell survival, as was demonstrated before in other cell lines [15] [16] [17] . After stimulation with H2O2, miR-155 levels increased 4-fold (Fig. 1A) (Fig. 2D, (Fig. S2 ). (Fig. S3) .
E). Improved cell survival was also found when performing a cell viability assay (Fig. 2C). Interestingly, no significant difference in the number of apoptotic cells was found when comparing CMPCs overexpressing pre-mir-155, anti-mir155 or scr-mir. To investigate whether necrosis was a primary result or a secondary event of apoptosis, we performed a time course experiment. In time, apoptosis remained a minor type of cell death, whereas, necrosis increased dramatically after 12 hrs of stimulation, being the predominant type of cell death
Additionally, we tested the activities of caspases in CMPCs upon stimulation by a homogeneous caspases assay, but we did not observe the presence of any enzymatic activity (data not shown). Taking together, our observations show that in CMPCs miR-155 increases cell survival upon oxidative stress by reducing necrotic cell death. To test whether changing miR-155 levels affect CMPC cardiomyogenic differentiation potential, we transfected pre-miR-155, anti-miR-155 or scr-miR into CMPCs and started differentiation experiments as previously reported [6]. We observed increased levels of TNNT2 and ventricular MYL2 1 week after the initiation of differentiation, similar as non-transfected CMPCs, indicating that miR-155 transfection did not affect cardiomyogenic differentiation potential
MiR-155 reduces necrotic cell death via targeting RIP1
RIP1 is a validated target for mir-155 in the response of macrophages to endotoxin shock [15] , required for death-receptor agonists activated necrosis [20] . Therefore, we tested whether miR-155 might inhibit necrosis by repressing RIP1.
We validated this in CMPCs and we showed that miR-155 repressed RIP1 expression both at the RNA and protein levels (Fig. 3A-C) . To test the functional relevance of RIP1 in the observed necrotic cell death, we used Nec-1, a specific inhibitor of RIP1 [24] , in oxidative-stress stimulated CMPCs. In Nec-1 treated CMPCs, cell survival improved and necrosis diminished to a similar extent as miR-155 overexpression (Fig. 3D) , with no changes in apoptosis. In addition, knockdown of RIP1 expression by siRNA treatment efficiently repressed RIP1 mRNA and protein levels ( Fig. 3E-G) , thereby preventing necrotic cell death and improving cell survival (Fig. 3H) (Fig. 4A, B) . Similarly, in the array focused on apoptosis-related genes, only BIRC3 and CASP1 showed a decrease of more than 4-fold (Fig. 4C, D) . These data confirm that cell survival and apoptosis pathways are not widely affected upon miR-155 overexpression. [21, [25] [26] [27] [28] [29] . The recognition of resident CPCs that could contribute to both myocardial regeneration and vascularization has provided an ideal candidate for cardiac repair. Previously we reported that upon transplantation CMPCs reduced the extent of left ventricular remodelling up to 3 months after MI [8] , thereby improving cardiac output. Due to the hostile environment of the ischemic heart, however, the survival of newly implanted cells remains problematic [12, 30] . Several strategies of preconditioning or stimulations are studied [31] [32] [33] [34] [35] . Although Fig. 1 (A) [39] . In apoptosis-deficient conditions, however, RIP1 has been found to be required for the activation of necrosis by deathreceptor agonists [20] . This process is termed necroptosis by Degterev et al. and they identified RIP1 as a key universal effector molecule, potentially followed by divergent downstream execution steps, depending on the cellular context [24] . Interestingly, RIP1 was described as a target for miR-155 in macrophages in their response to endotoxin shock [15] 
MiR-155 inhibits necrosis, independent of activation of Akt pro-survival pathway
Discussion
Cell-based therapy has emerged as a promising, alternative strategy to regenerate or improve function upon myocardial infarction (MI) and possibly for chronic heart failure. The feasibility of various cell sources and different cell delivery methods have been extensively explored
RIP1 emerged as a potential target candidate for miR-155 regulated inhibition of necrosis. RIP1, a death domain protein, is dispensable for the induction of death-receptor-mediated apoptosis
